Scholarlink

<p>Fragile X syndrome (FXS) is characterized by sensory hypersensitivity and neural hyperexcitability linked to GABAergic dysfunction. BAER-101, formerly known as AZD7325, is a positive allosteric modulator of GABA<sub>A</sub> receptors with functional selectivity for α2/α3 subunits, designed to enhance inhibitory tone while minimizing sedation associated with α1 activation. This study evaluated the acute and chronic effects of BAER-101 on behavioral and electrophysiological outcomes in individuals with FXS. The study employed a within-subject 3 × 2 factorial design, with three dosing conditions (Low Dose: 5&#xa0;mg; High Dose: 15&#xa0;mg; Placebo, all twice a day) and two time factors (Acute: same-day pre-/post-dose comparison; Chronic: after two weeks of consecutive dosing). Behavioral endpoints included clinician- and parent-rated symptom severity and laboratory measures of attention and memory, while electrophysiological endpoints comprised resting-state and auditory-evoked scalp-recorded 128-channel EEG metrics including bandpower, inter-trial coherence, and event-related potentials. Behavioral results showed limited evidence for improvements: across tasks, most effects were nonsignificant, with only marginal dose-related trends. The isolated findings lacked consistency or dose-dependence and are likely attributable to random variation. Test–retest reliability of behavioral measures was generally lower than published estimates (ICC ≈ 0.4–0.75), suggesting that measurement noise and small sample size may have obscured true drug effects. EEG spectral power analysis showed significant drug × time interactions, but follow-up comparisons did not support consistent pre-/post-drug changes, suggesting these effects reflected noise rather than drug response. ERP analyses indicated small, nonsystematic reductions in amplitude of onset-evoked potentials during chirp and habituation paradigms following BAER-101 treatment, without clear dose dependency. Test–retest reliability for EEG measures was lower than previously reported, with intraclass correlation coefficients ≈ 0.6 relative to prior work. Overall, no robust behavioral or electrophysiological improvements were observed with BAER-101 at the tested doses and durations.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Acute and chronic dosing of the GABA A alpha 2,3 selective agonist BAER-101 do not alter behavior but may impact auditory-evoked EEG responses in adults with fragile X syndrome

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月1日

查看全文
  • Lisa A. De Stefano,
  • Hyeonseok Kim,
  • Craig A. Erickson,
  • Ernest V. Pedapati,
  • Kelli C. Dominick,
  • Rebecca Shaffer,
  • Logan K. Wink,
  • Lauren M. Schmitt,
  • Makoto Miyakoshi

摘要

Fragile X syndrome (FXS) is characterized by sensory hypersensitivity and neural hyperexcitability linked to GABAergic dysfunction. BAER-101, formerly known as AZD7325, is a positive allosteric modulator of GABAA receptors with functional selectivity for α2/α3 subunits, designed to enhance inhibitory tone while minimizing sedation associated with α1 activation. This study evaluated the acute and chronic effects of BAER-101 on behavioral and electrophysiological outcomes in individuals with FXS. The study employed a within-subject 3 × 2 factorial design, with three dosing conditions (Low Dose: 5 mg; High Dose: 15 mg; Placebo, all twice a day) and two time factors (Acute: same-day pre-/post-dose comparison; Chronic: after two weeks of consecutive dosing). Behavioral endpoints included clinician- and parent-rated symptom severity and laboratory measures of attention and memory, while electrophysiological endpoints comprised resting-state and auditory-evoked scalp-recorded 128-channel EEG metrics including bandpower, inter-trial coherence, and event-related potentials. Behavioral results showed limited evidence for improvements: across tasks, most effects were nonsignificant, with only marginal dose-related trends. The isolated findings lacked consistency or dose-dependence and are likely attributable to random variation. Test–retest reliability of behavioral measures was generally lower than published estimates (ICC ≈ 0.4–0.75), suggesting that measurement noise and small sample size may have obscured true drug effects. EEG spectral power analysis showed significant drug × time interactions, but follow-up comparisons did not support consistent pre-/post-drug changes, suggesting these effects reflected noise rather than drug response. ERP analyses indicated small, nonsystematic reductions in amplitude of onset-evoked potentials during chirp and habituation paradigms following BAER-101 treatment, without clear dose dependency. Test–retest reliability for EEG measures was lower than previously reported, with intraclass correlation coefficients ≈ 0.6 relative to prior work. Overall, no robust behavioral or electrophysiological improvements were observed with BAER-101 at the tested doses and durations.